1. What Is the Peripheral Stent Market?
The Peripheral Stent Market covers balloon-expandable and self-expanding metallic stents, drug eluting peripheral stents, stent grafts, and covered stents deployed endovascularly to treat peripheral arterial disease in the iliac, femoral, popliteal, and renal arterial segments. Vascular surgeons, interventional radiologists, and interventional cardiologists at hybrid endovascular suites use Peripheral Stent devices to restore blood flow in patients with claudication, critical limb ischemia, and renovascular hypertension. The market spans nitinol self-expanding stents for femoral popliteal disease, balloon-expandable stents for renal and iliac lesions, covered ePTFE-lined stent grafts for aortoiliac disease, and drug-coated peripheral stents eluting paclitaxel or sirolimus. SVS and CIRSE clinical practice guidelines define indications for peripheral stenting versus surgical bypass across anatomical territories.
2. Peripheral Stent Market Size & Forecast
3. Emerging Technologies
- Nitinol self-expanding peripheral stents use shape-memory alloy construction to conform to the femoral popliteal artery during repetitive flexion, maintaining lumen patency with reduced fracture risk versus stiffer stainless steel platforms. Bard Peripheral Vascular's Lifestent and Medtronic's Complete SE represent the major commercial nitinol femoral popliteal stent platforms at vascular and endovascular programs.
- Drug-eluting peripheral stents apply paclitaxel or sirolimus to the nitinol stent surface, releasing drug locally to inhibit neointimal hyperplasia in the femoral popliteal artery during the first six months after deployment. Cook Medical's Zilver PTX remains the most extensively studied peripheral drug eluting stent, with five-year primary patency data supporting long-term efficacy in femoral popliteal disease.
- Covered endovascular stent grafts use an ePTFE or Dacron liner on a metallic scaffold to exclude lesions from blood flow, treating aortoiliac occlusive disease, peripheral aneurysms, and arteriovenous fistulas with a single endovascular device. Gore's Viabahn and Bard's Covera stent graft represent commercial covered stent products for femoral popliteal and arteriovenous dialysis access applications.
- Balloon-expandable renal artery stents use stiff platinum or stainless steel scaffolds to resist aortic recoil at the renal ostium after angioplasty of atherosclerotic renal artery stenosis. Medtronic's Express SD and Boston Scientific's Visi-Pro are commercial balloon-expandable stent platforms used for renal and mesenteric ostial stenting at vascular and interventional radiology programs.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Coronary Stent Market.
4. Key Market Opportunity
Within the Peripheral Stent Market, a leading opportunity is the growing adoption of drug eluting peripheral stents at femoral popliteal interventional programs upgrading from bare nitinol stent protocols, where published patency advantages and growing insurance reimbursement coverage for peripheral drug eluting stent procedures are driving product transition at high-volume endovascular centers. The expanding endovascular aortic aneurysm repair market generates consistent aortic stent graft demand as the prevalent pool of implanted devices grows and surveillance protocols generate secondary intervention requirements for endoleak management and graft limb extension. Infrapopliteal drug eluting stent and drug-coated balloon programs targeting below-the-knee arterial disease in critical limb ischemia represent a large incremental opportunity in a territory underserved by devices with proven long-term patency in small-diameter tibial vessels. Emerging market vascular surgery capacity expansion across Asia Pacific and Latin America generates volume demand for standard nitinol peripheral stents as newly trained endovascular specialists establish femoral popliteal intervention programs.
5. Top Companies in the Peripheral Stent Market
The following organisations hold leading positions in the Peripheral Stent Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Cook Medical (Zilver PTX)
- Medtronic (Endurant, IN.PACT)
- W.L. Gore (Excluder, Viabahn)
- Becton Dickinson (C.R. Bard)
- Boston Scientific
- Biotronik (Passeo-18)
- Cordis (Cardinal Health)
- Terumo
- Lombard Medical
- Angiotech
6. Market Segmentation
The Peripheral Stent Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product | Bare Metal Peripheral Stents Drug Eluting Peripheral Stents Covered Peripheral Stents Stent Grafts |
| By Material | Nitinol Stainless Steel Cobalt-Chromium |
| By Application | Femoral Popliteal Disease Iliac Disease Renal Artery Stenosis Infrapopliteal Disease |
| By End User | Hospitals Endovascular Surgery Centers |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Peripheral Stent Market trajectory over the forecast period:
Drug Eluting Peripheral Stents Are Improving Long-Term Patency in Femoral Popliteal Disease Over Plain Nitinol Bare Metal Stents.High restenosis rates of bare nitinol stents in the femoral popliteal artery, driven by repetitive flexion forces during ambulation, motivated drug-eluting peripheral stent platforms combining nitinol structure with local drug release to inhibit neointimal hyperplasia. Cook Medical's Zilver PTX paclitaxel-eluting polymer-free peripheral stent demonstrated consistent 12-month primary patency advantages in the ZILVER PTX randomized controlled trial, achieving FDA approval in 2012 and commercial adoption as the market-defining platform. The EMPOWER randomized controlled trial comparing Cordis's Symphony sirolimus-eluting peripheral stent against standard of care is among the next-generation studies generating additional evidence for the drug-eluting peripheral segment. Competitive entry of multiple sirolimus-eluting peripheral stent platforms is expected to reduce per-unit pricing while expanding institutional adoption at endovascular programs.
Transcatheter Aortic Stent Grafts Are Replacing Open Surgical Repair for the Majority of Abdominal Aortic Aneurysm Cases at High-Volume Vascular Programs.Endovascular aortic aneurysm repair using bifurcated stent graft systems has become the dominant treatment modality for infrarenal abdominal aortic aneurysm at high-volume centers, with registry data documenting lower 30-day perioperative mortality versus open surgical repair in patients with suitable anatomy. The DREAM and EVAR trials established the short-term mortality advantage of endovascular repair over open surgery, and long-term follow-up data have informed stent graft design improvements in subsequent generations. Medtronic's Endurant, Gore's Excluder, and Cook Medical's Zenith represent the major commercial bifurcated endovascular aneurysm repair platforms with the most extensive published clinical data. The shift to endovascular repair has generated a large stent graft maintenance market as implanted devices require imaging surveillance and secondary intervention for endoleak and migration.
Infrapopliteal Drug Eluting Stents Are Being Evaluated for Critical Limb Ischemia in Below-the-Knee Segments with High Treatment Failure Rates.Below-the-knee arterial disease in the tibial and peroneal segments is a common cause of critical limb ischemia in diabetic patients, and standard balloon angioplasty achieves poor long-term patency due to small vessel diameter and high calcification burden. Medtronic's IN.PACT 018 drug-coated balloon and Biotronik's Passeo-18 Lux are among the drug-coated peripheral devices being evaluated in below-the-knee applications, with drug eluting stent programs by Biosensors International targeting tibial arterial disease. The PREVENT IV tibial trial and similar infrapopliteal drug device studies are generating clinical evidence for treatment in the below-the-knee territory where limb salvage is the primary treatment goal. Successful infrapopliteal drug eluting stent data would represent a significant expansion of the peripheral drug device market.
For related market intelligence, see the Drug Eluting Stent Market.
8. Segmental Analysis
By product, the Bare Metal Peripheral Stents segment dominated the Peripheral Stent Market in 2025, representing the majority of femoral popliteal and iliac stenting volume at endovascular programs globally where nitinol self-expanding stents remain the workhorse device for routine peripheral arterial disease revascularization. The Drug Eluting Peripheral Stents segment is the fastest-growing product category, expanding as reimbursement coverage for peripheral drug eluting stent procedures improves and published patency data from registries and randomized trials support institutional protocol transitions from bare metal to drug eluting use in femoral popliteal disease.
By application, Femoral Popliteal Disease led overall market revenue, while Infrapopliteal Disease is registering the highest growth rate as below-the-knee drug device programs advance and critical limb ischemia treatment volumes grow with aging diabetic populations.
9. Regional Analysis
Regional demand patterns across the Peripheral Stent Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Peripheral Stent Market in 2025, accounting for approximately ~40% of global market revenue, driven by high peripheral arterial disease endovascular intervention volumes, established hybrid operating room and endovascular suite infrastructure at vascular and cardiac surgery programs, and the commercial leadership of Cook Medical, Medtronic, and W.L. Gore in the aortic stent graft and peripheral stent segments. Moreover, CMS reimbursement for endovascular peripheral arterial disease treatment procedures and growing clinical guideline support for drug eluting peripheral stents sustain institutional investment in peripheral stent product adoption. In addition, active FDA regulatory engagement on next-generation peripheral stent clearances has maintained a commercial launch pipeline supporting North American product availability. The established intervention infrastructure, reimbursement framework, and product development ecosystem sustain North American leadership in the Peripheral Stent Market through the forecast period.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Peripheral Stent Market through 2034, advancing at approximately ~12.5%, driven by increasing peripheral arterial disease prevalence linked to diabetes, hypertension, and smoking in aging populations across China, India, Japan, and Southeast Asia, expanding endovascular vascular surgery infrastructure at urban tertiary hospitals, and government health insurance reimbursement for peripheral arterial disease treatment procedures. The region benefits from growing domestic peripheral stent manufacturing in China, where regulatory-approved nitinol stent products compete on price with international brands at government hospital procurement programs. Moreover, medical tourism growth in Thailand and Malaysia is increasing endovascular procedure volumes at internationally accredited private hospitals specifying premium peripheral stent products. The combination of peripheral arterial disease burden growth, endovascular capacity expansion, and domestic manufacturing positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Peripheral Stent Market was valued at USD 2.51 Bn in 2025 and is projected to reach USD 5.63 Bn by 2034, growing at a CAGR of 9.4% over the 2026–2034 forecast period.
The Peripheral Stent Market is projected to grow at a CAGR of 9.4% from 2026 to 2034.
North America dominated the Peripheral Stent Market in 2025, accounting for approximately ~40% of global market revenue, driven by high peripheral arterial disease endovascular intervention volumes, established hybrid operating room and endovascular suite infrastructure at vascular and cardiac surgery programs, and the commercial leadership of Cook Medical, Medtronic, and W.L.
The leading companies in the Peripheral Stent Market include Cook Medical (Zilver PTX), Medtronic (Endurant, IN.PACT), W.L. Gore (Excluder, Viabahn), Becton Dickinson (C.R. Bard), Boston Scientific, Biotronik (Passeo-18), Cordis (Cardinal Health), Terumo, Lombard Medical, Angiotech.
Drug eluting peripheral stents are improving long-term patency in femoral popliteal disease over plain nitinol bare metal stents.
By product, the Bare Metal Peripheral Stents segment dominated the Peripheral Stent Market in 2025, representing the majority of femoral popliteal and iliac stenting volume at endovascular programs globally where nitinol self-expanding stents remain the workhorse device for routine peripheral arterial disease revascularization.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.